Vanderbilt First to Use Specialized PET/CT Scan to Uncover Cancerous Tumors

	Tweet

Vanderbilt University Medical Center and affiliated VA Tennessee Valley Healthcare System are the first in the U.S. to perform a specialized PET/CT scan to successfully locate the presence of tumors.

The improved imaging allows surgeons to more easily locate and remove cancerous tumors, according to Ronald Walker, M.D., professor of Radiology and Radiological Sciences.

Walker and Jeffrey Clanton, associate in Radiology and Radiological Sciences, performed the first U.S. diagnosis at Vanderbilt on a 49-year-old lung cancer patient.

“The current method of imaging tumors can best be described as trying to see the sun through the clouds,” Walker said. “But this new radiotracer removes all of the clouds.”

The 68Ga-DOTATATE PET/CT scan offers higher resolution and sensitivity locating tumors. Although performed in Europe, this specialized type of radiologic scan has been viewed in the U.S. as offering only limited benefit to a small number of cancer patients. However a recent increase of neuroendocrine cancers seen at Vanderbilt led Walker and his associates to more widely apply usage of this new technology.

Eric Liu, M.D., assistant professor of Surgery and a faculty member with the Vanderbilt-Ingram Cancer Center, is working with Walker and the Department of Nuclear Medicine to assemble a team of physicians, including surgeons, medical oncologists, endocrinologists, radiologists and nurses, who are actively preparing studies to test its effectiveness in locating neuroendocrine lesions.

“Our goal is to offer our patients the comfort and security of knowing that soon we will be able to see much more clearly with this tracer, and can then surgically remove all of their tumors - not just some of them,” Liu said. “We know that taking a comprehensive approach to both diagnostics and therapy will enable us to improve the lives of patients suffering from this all-too-often hidden disease.”

Vanderbilt expects to open a fully-operational neuroendocrine center in early 2011. Once opened, Liu and colleagues will begin clinical trials using the radiotracer and other modalities. Already, Vanderbilt treats several hundred patients with neuroendocrine cancer.

“Once we have this technology in place, we will be able to offer patients what no one else yet can,” said Naji Abumrad, M.D., the John L. Sawyers professor and chair of the Department of Surgery. “Accurately diagnosing the disease is just the first step. Soon we’ll be able to offer a variety of proven therapeutic treatments, including targeted chemotherapy, radiopeptide therapy and surgery.”

Source:  Vanderbilt University Medical Center

RELATED STORIES:
Insight into the anti-cancer effect of exercise   New process that can save at-risk cancer patients is effective and significantly less costly   New Study Begins for Kids With High-Risk Cancer   Errors in cancer diagnosis common, often harmful   People Living in Poverty at Greater Risk of Dying from Cancer   Health literacy tests underutilized; may improve elderly cancer patients’ care and outcomes   Scientists announce new advance with potential for future cancer targeting   Normalizing Tumor Vessels to Improve Cancer Therapy   Cancer survivors recognized for helping Philadelphia-area patients   How cancer cells stay young and aggressive   Cancer cure worth $50 trillion   Folic acid supplements may raise cancer risk: study   Radiation Treatment Prolonged Liver Cancer Patients’ Lives   Cancer drug may fight smallpox, study suggests   Cancer: The good news   US to look for early signs of cancer drug effects   Killing Cancer Like a Vampire Slayer   Smart bomb drug zaps cancer cells in mice   And the number one cancer myth is…   U.S. study faults aggressive end-of-life cancer care   Cancer-causing gene discovery suggests new therapies   Possible New Cancer Treatment Identified

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]